How Do Bispecific TCRs Differ From Other Immunotherapies?
Unlike CAR-T cells or monoclonal antibodies, bispecific TCRs can recognize peptides presented by human leukocyte antigen (HLA) molecules on the cancer cell surface. This capability allows them to target a broader range of antigens, including those that are intracellular and processed by the MHC pathway. This characteristic sets them apart from therapies that rely on extracellular antigen recognition.
